The content of the Figure 3 was adapted from the following references [3,52,83,94-111]
Although ApoA-I plays a central role in reverse cholesterol transport, and contributes to anti-atherosclerotic activity through CEC, therapeutic drugs targeting ApoA-I have not yet to be applied clinically, so we look forward to future developments
The final section of this review synthesizes these insights into a forward-looking perspective on the future of peptide therapeutics and articulates why the rediscovery of dormant biology, when guided by modern pharmacologic principles, may represent the most productive frontier in drug discovery
Which is better, Ipamorelin or CJC-1295
A quality clinic will clearly explain how treatment works, what side effects are possible, and what you can realistically expect